Evaluation of Time to Therapeutic Anticoagulation and Associated Outcomes in Critically Ill, Obese Patients With Pulmonary Embolism Receiving Unfractionated Heparin

2019 ◽  
pp. 089719001987807
Author(s):  
Lauren H. Sutton ◽  
Bethany R. Tellor ◽  
Hannah E. Pope ◽  
Jennifer N. Riney ◽  
Katherine L. Weaver
Keyword(s):  
Pulmonary Embolism ◽  
Unfractionated Heparin ◽  
Critically Ill ◽  
Obese Patients ◽  
Therapeutic Anticoagulation ◽  
Hemodynamic Deterioration ◽  
Clinically Significant ◽  
Poor Outcomes ◽  
The Relationship ◽  
Acute Pe

Background: Delays in time to therapeutic activated partial thromboplastin time (aPTT) have been associated with poor outcomes in patients with acute pulmonary embolism (PE). Objective: To investigate the relationship between time to therapeutic anticoagulation and in-hospital mortality in critically ill, obese patients with acute PE. Methods: This study examined 204 critically ill patients with a body mass index (BMI) ≥30 kg/m2 receiving unfractionated heparin (UFH) for PE treatment. Patients achieving therapeutic anticoagulation within 24 hours of UFH initiation (early) were compared to those in >24 hours (delayed). Additional end points included 30-day mortality, median time to therapeutic aPTT, proportion of therapeutic and supratherapeutic aPTT values, hemodynamic deterioration, thrombolytic therapy after UFH initiation, length of stay, and bleeding. Results: No difference in in-hospital or 30-day all-cause mortality was seen (odds ratio [OR]: 1.33, confidence interval [CI]: 0.647-2.72; OR: 1.003, CI: 0.514-1.96). Patients in the early group had a greater proportion of therapeutic aPTT values (66.7% vs 50%, P < .001) and higher percentage of supratherapeutic aPTT values (20.9% vs 11.3%, P < .001); however, no increase in clinically significant bleeding was evident (15.2% vs 10.9%, P = .366). Conclusion: In this population, a shorter time to therapeutic aPTT was not associated with improved survival.

Prevalence of thrombocytosis in critically ill patients and its association with symptomatic acute pulmonary embolism

2013 ◽  
Vol 109 (02) ◽  
pp. 272-279 ◽  
Author(s):  
Shaila Chavan ◽  
Kwok Ho
Keyword(s):  
Pulmonary Embolism ◽  
Intensive Care ◽  
Platelet Count ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Acute Pulmonary Embolism ◽  
Increased Risk ◽  
Wide Range ◽  
The Relationship ◽  
Acute Pe

SummaryIt is uncertain whether thrombocytosis without underlying myeloproliferative diseases is associated with an increased risk of acute pulmonary embolism (PE). We investigated the relationship between thrombocytosis and risk of symptomatic acute PE, and whether Pulmonary Embolism Severity Index (PESI) was reliable in predicting mortality of acute PE. This multicentre registry study involved a total of 609,367 critically ill patients admitted to 160 intensive care units (ICUs) in Australia or New Zealand between 2006 and 2011. Forward stepwise logistic regression was used to assess the relationship between risk of acute PE and platelet counts on intensive care unit (ICU) admission. Acute PE (n=3387) accounted for 0.9% of all emergency ICU admissions. Over 20% of all PE required mechanical ventilation, 4.2% had cardiac arrest, and the mortality was high (14.8%). Thrombocytosis, defined by a platelet count >500×109 per litre, occurred in 2.1% of the patients and was more common in patients with acute PE than other diagnoses (3.4 vs. 2.0%). The platelet counts explained about 4.5% of the variability and had a linear relationship with the risk of acute PE (odds ratio 1.19 per 100×109 per litre increment in platelet count, 95% confidence interval 1.06–1.34), after adjusting for other covariates. The PESI had a reasonable discriminative ability (area under receiver-operating-characteristic curve = 0.78) and calibration to predict mortality across a wide range of severity of acute PE. In summary, thrombocytosis was associated with an increased risk of symptomatic acute PE. PESI was useful in predicting mortality across a wide range of severity of acute PE.

Association of anaemia and mortality in patients with acute pulmonary embolism

2009 ◽  
Vol 102 (07) ◽  
pp. 153-158 ◽  
Author(s):  
Carlos Escobar ◽  
David Martí ◽  
Gema Díaz ◽  
Jesús César ◽  
Ángel García-Avello ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Inferior Vena ◽  
Independent Predictor ◽  
Vena Cava ◽  
Female Gender ◽  
All Cause Mortality ◽  
Diagnosis Of Cancer ◽  
The Relationship ◽  
Mortality Hazard Ratio ◽  
Acute Pe

SummaryThis study aimed to evaluate the relationship between anaemia and pulmonary embolism (PE) prognosis. We analysed a cohort of 764 patients with acute PE referred to a single center for diagnosis and management. Patients were divided into groups by quartiles of haemoglobin (Hb): Hb < 11.7 g/dl; Hb 11.7 to 12.9 g/dl; Hb 13.0 to 14.1 g/dl; Hb > 14.1 g/dl. Patients had a mean Hb of 12.9 g/dl, and values ranged from to 4.3 to 19.5 g/dl. Lower Hb was associated with recent bleeding, an impaired haemodynamic profile and higher creatinine. Patients in the lower Hb quartiles more commonly had female gender (p < 0.001), a diagnosis of cancer (p < 0.001), and an indication for an inferior vena cava (IVC) filter (p < 0.002), compared to patients in the higher Hb quartiles. Patients in higher Hb quartiles had higher survival at three months (75%, 86%, 90% and 91% for lowest to highest quartiles, respectively). On multivariate analysis, adjusting for known PE prognostic factors, low Hb proved to be an independent predictor of mortality (hazard ratio [HR] 1.16, 95% confidence interval [CI] 1.05 to 1.28 for each decrease of 1 g/dl). Hb level remained an independent predictor of all-cause mortality when cancer patients were excluded from the analysis (adjusted HR 0.81; 95% CI, 0.66 to 0.99; p = 0.04). Moreover, patients with anaemia showed a higher risk of fatal PE (unadjusted HR 1.19, 95% CI 1.04 to 1.37). In conclusion, in patients with acute symptomatic PE, anaemia severity is associated with worsened survival.

scholarly journals Effect of Persistent Thrombocytopenia on Mortality in Surgical Critical Care Patients

2016 ◽  
Vol 23 (1) ◽  
pp. 84-90 ◽  
Author(s):  
Qin Wu ◽  
Jianan Ren ◽  
Gefei Wang ◽  
Guanwei Li ◽  
Nadeem Anjum ◽  
...  
Keyword(s):  
Critical Care ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Surgical Intensive Care Unit ◽  
Surgical Intensive Care ◽  
Surgical Critical Care ◽  
Hospital Stays ◽  
Clinically Significant ◽  
The Relationship ◽  
Persistent Thrombocytopenia

Thrombocytopenia is common among surgical critically ill patients. The relationship between the duration of thrombocytopenia and mortality is not well studied. This retrospective 12-month cohort study was designed to evaluate the association between persistent thrombocytopenia and mortality among surgical critically ill patients to determine the risk factors for persistent thrombocytopenia. The study included adult patients consecutively admitted to the surgical intensive care unit (SICU) at our institution. Patients with a diagnosis of thrombocytopenia were identified from a prospective critical care database. We defined patients with persistent thrombocytopenia as those with thrombocytopenia lasting more than 7 consecutive days. The primary outcome of this study was 28-day mortality and the secondary outcomes were lengths of SICU stay and hospital stay. Fifty-one patients experienced persistent thrombocytopenia and 71 experienced nonpersistent thrombocytopenia. Among patients with persistent thrombocytopenia, mortality was significantly higher, and SICU and hospital stays were longer than those with nonpersistent thrombocytopenia. Risk factor analysis failed to predict which patients with thrombocytopenia would develop into persistent thrombocytopenia. Persistent thrombocytopenia is a clinically significant disorder and is associated with poorer outcomes. Future studies are needed to further define this process.

scholarly journals Hypertriglyceridemia in Critically Ill Patients With SARS-CoV-2 Infection

2021 ◽  
pp. 106002802110383
Author(s):  
Wasim S. El Nekidy ◽  
Abdullah Shatnawei ◽  
Manal M. Abdelsalam ◽  
Mariam Hassan ◽  
Ruba Z. Dajani ◽  
...  
Keyword(s):  
Critically Ill ◽  
Critically Ill Patients ◽  
Case Reports ◽  
Severe Disease ◽  
Critical Care Admission ◽  
Full Picture ◽  
Inflammatory State ◽  
Clinically Significant ◽  
The Relationship ◽  
Over Time

Background Patients with SARS-CoV-2 infection could develop severe disease requiring critical care admission. Case reports indicated high incidence of hypertriglyceridemia (HTG) in critically ill patients infected with SARS-CoV-2, which might be related to the drugs. Objective We sought to determine the risk factors associated with HTG in this population and to investigate the relationship between HTG and lipase. Methods A retrospective observational study was conducted at our hospital between March 1 and June 30, 2020. Patients were included if they were ≥18 years old, admitted to the intensive care unit (ICU), tested positive for SARS-CoV-2, and had triglycerides (TG) checked during their hospital stay. Results Of the 111 critically ill patients, 103 patients were included. Males comprised 88.3% of the sample. The median TG at baseline was 197.4 (IQR: 139.8-283) mg/dL. The lipase median level at baseline was 23.00 (IQR: 0.00-69.50) IU/L. The results of the mixed-effects logistic regression analysis indicated that patient-level variables, favipiravir use, blood glucose level, and propofol use were significantly associated with HTG. There was no relationship between lipase and TG levels over time. Furthermore, TG concentrations over time showed a similar trend to inflammatory markers. Conclusion and Relevance The incidence of clinically significant HTG was high and was associated with propofol and favipiravir use. HTG might reflect the high inflammatory state in these patients. Clinicians should look at the full picture before changing therapies based only on HTG. Our findings need to be replicated in a larger prospective study.

scholarly journals Brain Natriuretic Peptide, Troponin and D-Dimer Levels in Relation to Long-Term Functional Outcome after a First Episode of Pulmonary Embolism: Results from the E.L.O.P.E. Study

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 649-649
Author(s):  
Susan R Kahn ◽  
Andrew Hirsch ◽  
Margaret Beddaoui ◽  
Arash Akaberi ◽  
David Anderson ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Relative Risk ◽  
Brain Natriuretic Peptide ◽  
First Episode ◽  
Increased Risk ◽  
The Relationship ◽  
Acute Pe ◽  
D Dimer ◽  
Age And Sex

Abstract Background: Biomarkers such as brain natriuretic peptide (BNP), high-sensitivity cardiac troponin (hsTnT) and d-dimer (DD) are useful for acute or short-term risk stratification after pulmonary embolism (PE) to predict right ventricular dysfunction, recurrent PE or death. However, whether acute or convalescent levels of these biomarkers predict longterm functional limitation after PE has not been evaluated. To address this knowledge gap, we performed the ELOPE (Evaluation of Longterm Outcomes after PE) Study, a prospective, observational, multicenter cohort study of long-term outcomes after acute PE (www.clinicaltrials.gov NCT01174628). Objectives: To describe levels of NT-proBNP, hsTnT and d-dimer at baseline and 6 months in patients with acute PE, and to assess the relationship between biomarker levels and functional status at 1 year. Methods: Patients ³ 18 years old with a 1st episode of acute PE diagnosed within the previous 10 days screened at 5 Canadian recruiting centers were potentially eligible to participate. Exclusion criteria were subsegmental-only PE, preexisting severe cardiopulmonary comorbidity, previous proximal DVT, contraindication to CT pulmonary angiography (CTPA), life expectancy <1 year, unable to read questionnaire in English and French or to attend follow-up visits, and unable or unwilling to consent. Patients attended study visits at baseline, 1, 3, 6 and 12 months. Blood samples to assay NT-proBNP (serum), hsTnT (serum) and DD (plasma) were obtained at baseline and 6 months. NT-proBNP and hsTnT were measured using the cobas® 8000 modular analyzer (Roche Diagnostics, Laval, Quebec); cut-off for normal is <300pg/mL and <15ng/mL, respectively. DD was measured with the immune-turbidimetric STA®-Liatest® assay run on a STA® analyser (DiagnosticaStago, Asnieres, France); cut off for normal is <500ug FEU/L. The primary outcome for the ELOPE Study was maximal aerobic capacity as defined by peak oxygen uptake (VO2) as a percent of predicted maximal VO2 (VO2max) on a cardiopulmonary exercise test (CPET) performed at the 1-year visit, with <80% predicted VO2max considered abnormal, as per American Thoracic Society guidelines. For each biomarker at baseline and 6 months, we calculated median (IQR) values, % of values above the cutoff, and univariate relative risk (RR) for VO2max <80% predicted on 1-year CPET (see Table). Multivariate logistic regression analysis (multiple log-binomial regression) was done, adjusted for age and sex, to assess the relationship between NT-proBNP, hsTnT, DD and 1-year CPET result. Results: 984 patients were screened for participation; of these, 150 were eligible and 100 (67%) consented to participate. Mean (SD) age was 50 (15) years, 57% were male, 80% were outpatients, and 33% had concomitant DVT. PE was provoked in 21% and unprovoked in 79%; none were cancer-related. Table. Median biomarker values, % of values above cutoff, and univariate RR for VO2max <80% predicted on 1-year CPET Variable NT-proBNP (pg/mL) hsTroponin T (ng/L) D-Dimer (ug FEU/L) Visit Date Baseline 6 months Baseline 6 months Baseline 6 months Median (IQR) 46 (21, 98) 37 (21, 81) 6 (3, 11) 5 (3, 8) 1230 (550, 2050) 200 (110, 370) N (%) > cut-off* 8 (10.1%) 4 (5.8%) 8 (10.1%) 5 (7.2%) 62 (78.5%) 8 (11.6%) Univariate RR for VO2 max <80% predicted at 1 year 1.74(0.99, 3.04) 1.15(0.41, 3.18) 1.34(0.66, 2.71) 0.44(0.07, 2.57) 1.42(0.66, 3.06) 0.84(0.33, 2.14) *Cut-offs: see Methods In a multiple model adjusted for age and sex, baseline NT-proBNP >300 pg/mL was associated with a relative risk (RR) of 2.31 (95% CI 1.10, 4.86; p=0.027) for VO2max <80% predicted on 1-year CPET, whereas DD and hsTnT did not influence this risk. Conclusion: In a prospective cohort of patients with a first episode of PE without preexisting severe cardiopulmonary comorbidity, baseline NT-proBNP >300 pg/mL predicted a greater than 2-fold increased risk of abnormal CPET at 1 year after PE. This finding may allow early identification of PE patients at increased risk of poor longterm outcome after PE. Further analyses are in progress to assess the relationship between changes in biomarker levels from baseline to 6 months and 1-year CPET result. Funding: Canadian Institutes of Health Research (MOP-93627) Disclosures Wells: BMS/Pfizer: Research Funding; Bayer: Honoraria.

Unfractionated heparin dosing for therapeutic anticoagulation in critically ill obese adults

2015 ◽  
Vol 30 (2) ◽  
pp. 395-399 ◽  
Author(s):  
E.M. Hohner ◽  
R.M. Kruer ◽  
V.T. Gilmore ◽  
M. Streiff ◽  
H. Gibbs
Keyword(s):  
Unfractionated Heparin ◽  
Critically Ill ◽  
Obese Adults ◽  
Therapeutic Anticoagulation

957: EVALUATION OF WEIGHT-BASED DOSING OF UNFRACTIONATED HEPARIN IN CRITICALLY ILL OBESE PATIENTS

2020 ◽  
Vol 48 (1) ◽  
pp. 458-458
Author(s):  
Hannah Adams ◽  
Angela Righi ◽  
Melissa Fowler ◽  
Jaimini Patel
Keyword(s):  
Unfractionated Heparin ◽  
Critically Ill ◽  
Obese Patients

Is there a link between lung parenchyma lesions , BMI , CRP , D-dimer and acute pulmonary embolism in patients infected with COVID-19 ?

2021 ◽  
Vol 21 ◽  
Author(s):  
Amer Hamadé ◽  
Lucas Jambert ◽  
Jonathan Tousch ◽  
Philippe Feuerstein ◽  
Karima Hammas ◽  
...  
Keyword(s):  
Risk Factors ◽  
Pulmonary Embolism ◽  
Acute Pulmonary Embolism ◽  
Lung Parenchyma ◽  
Lower Limbs ◽  
Nasopharyngeal Swab ◽  
Therapeutic Anticoagulation ◽  
Venous Thromboembolic Events ◽  
Acute Pe ◽  
D Dimer

Introduction: ince the outbreak of the COVID-19 pandemic , increasing suggests that infected patients present a high incidence of venous thromboembolic events (VTE). The main objective of this retrospective study was to evaluate the prevalence of acute pulmonary embolism (PE) on pulmonary computer tomography angiograms (CTPA) in patients classified as COVID-19 infection. The second objective was to determine if there is a link between D-dimer levels, serum C-reactive protein (CRP ), body mass index (BMI) , the lung parenchyma lesions (LPL) and acute pulmonary embolism (PE) in these patients. Material and Methods: 120 patients with mean age 65 ±14.5 years infected with COVID- 19 underwent in our institution a CTPA for suspected PE .Thirty four were in intensive care units (ICU). A COVID-19 diagnosis was made by transcriptase polymerase chain reaction by means of nasopharyngeal swab or by chest CT images. Demographics and co-morbidities characteristics were collected . Laboratory parameters were automatically extracted from our heath information system. When PE was suspected a CTPA were acquired after injection of high concentration iodine contrast media .The criterion of suspected PE were based on the clinical respiratory deterioration , with an increased need for oxygen. A venous duplex ultrasound (DU) test of lower limbs was performed on admission. Results: CTPA showed 24 acute PE (20%) , of which 11 primary and 13 associated with deep venous thrombosis diagnosed on DU .Eleven of the 24 (45.8 %)had PE despite preventive and therapeutic anticoagulation with low molecular weight heparin with Enoxaparin (7 with preventive anticoagulation and 4 had therapeutic dose), of them 8 (72.7%) with risk factors for VTE .Acute PE was not significantly associated with CRP and LPL. However , we found a significant association between acute PE and BMI (mean 32.41±5.90 versus 27.1± 5.2 kg/m2, p 0.0007) or D-dimer Levels (mean 6040±5068 versus 3396.7±5361.5 ng/ml ,p <0.0001). Conclusions: Hospitalized patients infected with COVID-19 in conventional units or ICU have a high frequency of PE justifying preventive anticoagulation. For those who have a risk factors for VTE a therapeutic anticoagulation may be indicated.

Sign in / Sign up

Export Citation Format

Share Document